Physiomics signs new agreement with Cancer Research UK
Anita Riotta
Company News- 2 min read
10:10, 8th July 2019

Physiomics, a tech-based company aimed at predicting the effects of cancer treatment regimens, has signed an agreement to work with Bicycle Therapeutics and Cancer Research UK.

Physiomics is entering the project to analyze the data results of a Phase I/IIa clinical trial, sponsored by Cancer Research UK, of Bicycle Therapeutics’ lead program, BT1718.

Cancer Research is the United Kingdom’s leading cancer research charity and this new collaboration represents another partnership with a giant for Physiomics, who in the past has also teamed up with Merck & Co, and Bayer.

For more news and updates on Physionomics: FOLLOW

Disclaimer & Declaration of Interest

The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.

Login or register to post comments

Recent Articles